Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Breast cancer
2019 Standout
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
2010
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
2008
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial
2004
Use of Vancomycin-Containing Lock or Flush Solutions for Prevention of Bloodstream Infection Associated with Central Venous Access Devices: A Meta-Analysis of Prospective, Randomized Trials
2006
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
2008
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
LANGERHANS CELL HISTIOCYTOSIS RESEARCH
1998
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
2001
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial
1996
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials
2006
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Gemcitabine Plus Cisplatin for the Treatment of Metastatic Breast Cancer
2002
Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study
1997
The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
2007 Standout
Second line chemotherapy for NSCLC: establishing a gold standard
2002
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
2004
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Antibody therapy of cancer
2012 Standout
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012
Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients
2007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement
2004
Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review
2000
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
A Review of Risk Factors for Catheter-Related Bloodstream Infection Caused by Percutaneously Inserted, Noncuffed Central Venous Catheters
2002
Cancer treatment and survivorship statistics, 2012
2012 Standout
Physical activity and cancer prevention: a systematic review of clinical trials
2011
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Platinum Compounds in the Treatment of Advanced Breast Cancer
2001
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment
2010
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2010 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
2019 Standout
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
2012
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Gastrointestinal toxicities of novel agents in cancer therapy
2009
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Cardiotoxicity of cytotoxic drugs
2003
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
2005
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Chemotherapy of advanced non-small cell lung cancer
1999
Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations
2015
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Oxidative DNA damage: mechanisms, mutation, and disease
2003 Standout
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
2016
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2000
Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
2005
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
Cardiotoxicity of Cancer Therapy
2005
Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT3 pathways
2002
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
2013
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Expression of a Functional Eotaxin (CC Chemokine Ligand 11) Receptor CCR3 by Human Dendritic Cells
2002 StandoutNobel
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
2005
Cardiovascular Complications of Cancer Therapy
2004
Works of Anna Efremidis being referenced
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party
2007
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1998
First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer
2005
Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study
2001
Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines
2000
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
2007
Ifosfamide cardiotoxicity in humans
1989
Elevated Serum Leptin Levels: A Risk Factor for Non-Small-Cell Lung Cancer?
2008
The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation
1999
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation
1995
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy
2004
Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial
2002
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
Control of irinotecan-induced diarrhea by octreotide after loperamide failure
2001
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer
2002
Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I
2004
Central venous catheter-related infections after bone marrow transplantation in patients with malignancies: a prospective study with short-course vancomycin prophylaxis.
1995
Acute myelogenous leukemia following complete remission of small cell carcinoma of the lung
1986
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1994
Hodgkin's lymphoma in an adolescent with systemic lupus erythematosus
1984
A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC)
2006